Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $187M rose 12.8% year over year, in line with the +12.5% change in trailing-twelve-month research & development. Sequentially, it fell 7.9% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Research & development amounted to 111.4% of revenue in FY2025, down 13.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.8% holds above the trailing-twelve-month pace of +12.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$187M-7.9% QoQ
Last fiscal yearDec 2025
$750M+7.5% YoY
LTMMar 2026
$770.95M+12.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%——
1 year+7.5%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
750M USD
Year-over-year change
+7.5%
4-year CAGR
+10.8%

Research & Development vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 research & development of $770.95M is the 2nd highest of the 11 companies compared; the peer median is $178.75M.
  • Its year-over-year change of +12.5% is the 4th highest of 11, against a peer median of +2.3%.
  • Research & development amounts to 115.2% of revenue for RARE, versus a peer median of 181.7%.
RARE Competitors Peer median
Research & Development for RARE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$181.1B +19955.1%+12.4%17.6%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M +12.5%+2.0%115.2%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$530.96M +12.1%+6.1%74.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$433.31M -14.7%-11.3%43.0%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M -14.3%-5.0%—
QUREuniQure N.V.LTM Mar 2026$132.76M -4.7%-10.7%733.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$128.82M +9.2%+14.8%161.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M -28.8%-2.5%181.7%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M -12.8%-16.7%3625.8%
Peer median (excluding RARE) $178.75M+2.3%-2.3%181.7%

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.